BioSpace News Archive

QPS is a GLP/GCP-compliant and CLIA-certified contract research organization delivering discovery, preclinical, and clinical drug development services since 1995.

Calithera Biosciences, Inc. announced that the compensation committee of the company’s board of directors granted two new employees a non-qualified stock option to purchase an aggregate of 15,200 shares of Calithera’s common stock, at a per share exercise price of $5.82, the closing trading price on May 29, 2020.

Program will fund 11 unique solutions for challenges posed by COVID-19 from Canadians across the country

– Combined Company Will Operate as Chinook Therapeutics and Advance Pipeline of Clinical-Stage Programs in Kidney Diseases, Led by Atrasentan and BION-1301 in IgA Nephropathy – Combined Company Will be Well-Funded With Cash Position of ~$200 Million Expected at Closing, Including $25 Million in Additional Investment Committed by Chinook’s Existing Investors – Multiple Clinical and Regulatory Pipeline Milestones Planned for Combined Company Over the Next 12-18 Months – Companies to H

CalciMedica Inc., a clinical-stage biotechnology company targeting calcium release-activated calcium channels for the treatment of acute and severe inflammatory diseases including acute viral pneumonia in COVID-19 patients, announced the appointment of Robert N. Wilson, a former vice chairman of the Johnson & Johnson board, to the Company’s board of directors as co-chairman with current board chairman, Robert McNeil, Ph.D.

Representing a new era in digital radiography, Konica Minolta Healthcare Americas, Inc., announces the commercial availability of the KDR ® Advanced U-Arm, incorporating the award winning Dynamic Digital Radiography (DDR) capability. The KDR U-Arm with DDR recently received FDA clearance. DDR, or X-ray that Moves, provides a series of individual digital images acquired at high speed and low dose. The resulting cine loop presents a diagnostic-qual

Research collaboration will conduct in vivo testing of lead kidney and islet xenotransplant programs and validate platform in other organs

Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, provided today operational updates in advance of the filing of its 10-K for the year ended December 31, 2019 and its 10-Q for the first quarter of 2020. “We look forward to reporting our financial results for the full year 2019 in our Form 10-K upon the completion of our audit for the year-ended December 31, 2019 and for the first quarter of 2020 in our F

HTG Molecular Diagnostics, Inc., a life science company whose mission is to advance precision medicine, announced its HTG EdgeSeq technology was highlighted in several posters presented at the American Society of Clinical Oncology 2020 Virtual program.

Ehave enters lucrative Market Slated to Grow from $34.28 billion in 2018 $185.66 billion by 2026